Predictive factors for early mortality after regorafenib or trifluridine/tipiracil initiation in metastatic colorectal cancer

Key Points

• This research aims to identify factors that predict early mortality in patients starting regorafenib or trifluridine/tipiracil for metastatic colorectal cancer.
• Developed a predictive model based on patient data.
• Analyzed early mortality rates in relation to specific treatments.
• Supported decision-making in clinical settings.
• Identified key risk factors for early mortality.
• Suggested guidelines for clinicians in treatment planning.
• Emphasized the importance of tailored patient care.